Investor Relations

Merrimack is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of cancer. Merrimack applies its systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has six targeted therapeutic oncology candidates in clinical development.

View all »   RSSRecent Releases

May 14, 2015
Merrimack Pharmaceuticals Announces Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting

May 7, 2015
Merrimack Pharmaceuticals Reports First Quarter 2015 Financial Results

May 5, 2015
Merrimack Pharmaceuticals Announces Initiation of a Phase 2 Front-line Clinical Trial of MM-141 in Biomarker-Selected Patients with Metastatic Pancreatic Cancer

May 4, 2015
Baxter Bioscience and Merrimack Pharmaceuticals Announce Filing for European Approval of MM-398, an Investigational Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

View all »Events & Presentations

Jun 2, 2015 at 3:30 PM ET
Jefferies 2015 Global Healthcare Conference

Stock Quote (NASDAQ: MACK)

Price:
12.56

Change:
+ 0.10

Day High:
12.69

Day Low:
12.38

Volume:
580,800

4:00 PM ET on May 22, 2015
Delayed ~20 min. By eSignal.

Shareholder Tools